Premium
Improving the prognosis of pediatric hodgkin lymphoma in developing countries: A moroccan society of pediatric hematology and oncology study
Author(s) -
Hessissen Laila,
Khtar Rachida,
Madani Abdellah,
El Kababri Maria,
Kili Amina,
Harif Mhamed,
Khattab Mohamed,
Sahraoui Souha,
Benjaafar Nouredine,
Ahid Samir,
Howard Scott C.,
Benchekroun Said
Publication year - 2013
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24534
Subject(s) - medicine , procarbazine , vincristine , prednisone , copp , oncology , pediatrics , cyclophosphamide , chemotherapy , heme , biochemistry , chemistry , heme oxygenase , enzyme
Background The event‐free survival (EFS) of children with Hodgkin lymphoma (HL) exceeds 80% in high income countries (HIC), but little is known about this rate in developing countries. Procedure A prospective national protocol for children with classical HL was implemented in Morocco to increase EFS by careful risk stratification, providing each cycle of therapy on time, decreasing treatment abandonment, improving communication among healthcare providers, and improving data collection. Patients were stratified into a favorable risk group (Ann Arbor stages I and II, no B symptoms, no bulky disease, and no contiguous (E) lesions) and received four cycles of vinblastine, doxorubicin, methotrexate, and prednisone (VAMP) or an unfavorable risk group (all others) who received two cycles of vincristine, procarbazine, prednisone, and doxorubicin (OPPA) and four cycles of cyclophosphamide, vincristine, procarbazine, and prednisone (COPP). All patients received involved‐field radiotherapy 25.5 Gy after completion of chemotherapy. EFS was calculated counting death, relapse/resistant disease, and abandonment as events. Results From February 2004 to December 2007, 160 patients enrolled; 138 (86%) had unfavorable risk features. Twenty patients (12.5%) abandoned treatment, 16 relapsed or had resistant disease, and 6 died (3 unexplained, 2 varicella, and 1 suicide). The estimated 5‐year EFS was 70 ± 4% and overall survival 88 ± 3%. Conclusions Good outcomes for pediatric HL patients can be achieved in LMIC using a multidisciplinary team approach, uniform protocol‐based therapy, twinning partnership among oncology units in‐country and abroad, and a data collection system to monitor compliance and identify gaps in care. Pediatr Blood Cancer 2013;160:1464–1469. © 2013 Wiley Periodicals, Inc.